The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement.

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement.

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of ...

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of ...